ScreenerHero

SERSerina Therapeutics Inc. Common Stock

AMEX · US · Healthcare · Biotechnology · serinatherapeutics.com
2.870USD+5.51%Mkt Cap: 72.90M $P/E: —

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap72.90M $
Enterprise Value48.04M $
Revenue (TTM)0 $
Gross Profit-14.07M $
Net Income (TTM)-19.18M $
Revenue/Share0.0000 USD
Last Price2.870 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.73
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/SInfinity
P/B3.37
EPS (TTM)-1.87
EPS (Forward)-1.05
52W Range
1.22025% of range7.920
52W High7.920 USD
52W Low1.220 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE51843.24%
ROA-275.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.95M $
CapEx (TTM)59.00K $
FCF Margin—
FCF Yield-16.94%
Net Debt-19.27M $
Net Debt/EBITDA0.75
Balance Sheet
Debt/Equity-84.92
Current Ratio6.65
Quick Ratio6.12
Book Value/Sh0.8520 USD
Cash/Share0.9060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split28:1000
Split DateMar 15, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.500 USD
Upside (mean)+231.0%
Target Range8.000 USD – 11.00 USD
$8.000+231.0% to mean$11.00
# Analysts2
Ownership
Shares Out.25.40M
Float11.15M
Insiders50.75%
Institutions5.55%
Short Interest
Short Ratio5.7d
Short % Float1.94%
Short % Out.1.49%
Shares Short222.92K
Short (prev mo.)285.43K
Technical
SMA 502.158 (+33.0%)
SMA 2002.366 (+21.3%)
Beta-0.00
S&P 52W Chg18.16%
Avg Vol (30d)53.13K
Avg Vol (10d)89.15K
Technical Indicators
RSI (14)71.0
MACD0.2170
MACD Signal0.1730
MACD Hist.+0.0440
BB Upper3.095 USD
BB Middle2.399 USD
BB Lower1.703 USD
BB Width58.00%
ATR (14)0.1958 USD
Vol Ratio (20d)0.77x